Evaluating Efficacy and Safety of Danazol in Severe Hematologic or Pulmonary Disease Related to Telomeropathy

Phase 1

• Conditions: Telomere Length, Mean Leukocyte; Telomere Shortening
• Interventions: Drug: Danazol 200 MG

• Registration Number: NCT03710356
• Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Brief Summary

Constitutional mutations of genes involved in telomere repair and maintenance are responsible for "telomeropathy" (" Congenital Dyskeratosis "). Attrition of telomeres promotes cell senescence and genetic instability. The penetrance and severity of organ damage (pulmonary, hematological, liver, and neurological) is variable, depending on the gene involved, the generation concerned (anticipation phenomenon) and also environmental factors.

In cases of bone marrow failure, the only curative treatment is hematopoietic stem cell transplant, often limited by pulmonary and / or hepatic involvement or the absence of a suitable HLA match donor. The pulmonary phenotype is most often that of idiopathic pulmonary fibrosis. In severe forms, a lung transplant is proposed in the absence of contraindications. Anti-fibrotic treatments are not very effective or not evaluated. The observed decrease in the vital capacity of these patients is 300 ml / year, abnormally high compared to idiopathic forms. Evolution without transplant is in both situations rapidly unfavorable; the prognosis after lung or marrow transplant is also worse than that of similar transplants without telomeres disease.

Danazol has been used for over 4 decades in acquired and constitutional bone marrow failure in the absence of a therapeutic alternative. In telomeropathy, retrospective data on small cohorts indicate a haematological response rate of 60-70%. A prospective study in the United States recently showed a haematological response at 1 year in 78% of cases (10 of 12 evaluable patients) with stabilization of vital capacity. Retrospective data (unpublished) on patients treated in France have shown more side effects and more frequent treatment interruptions and eventually weaker haematological response rate. This study aim to evaluate the benefit of danazol at 12 months on the clinical response.

Detailed Description

Not available

Study Timeline

• Status Verified: 2018-10
• Study First Submitted: 2018-10-10
• Study First Submitted QC: 2018-10-15
• Last Update Submitted: 2018-10-15
• Study First Posted: 2018-10-18
• Last Update Posted: 2018-10-18
• Study Start: 2018-10-20
• Primary Completion: 2021-10-20
• Study Completion: 2022-10-20

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• with telomeropathy defined by the existence of a deleterious constitutional mutation of a gene involved in telomere maintenance (TERT, TERC, DKC1, TINF2, RTEL1, PARN, ACD, NHP2, NOP10, NAF1, WRAP53, CTC1, ERCC6L2, USB1, POT1, DNAJC21 or a newly identified gene responsible for telomeropathy ),
• 15 years or older,
• with severe haematological involvement (platelets < 20 G/L or ANC < 0.5 G/L and/or hemoglobin < 8 g/dL and/or transfusion needs) and/or pulmonary fibrosis with parenchymal involvement greater than 10% on the CT scan.
• being able to give informed consent for patients 18 years and older,
• being able to give consent and have the consent of the holder (s) of parental authority for children over 15 years,
• being a beneficiary of social security scheme.

Read More

Exclusion Criteria

• with HIV infection or active hepatitis B or C infection,
• with severe hepatic disease: ASAT and/or ALAT > 5N, or direct bilirubinemia > 30 μmol/L, TP <50% (except vitamin K deficiency),
• having an active or treated tumor pathology for less than 5 years with the exception of a basocellular carcinoma or a in situ carcinoma of the cervix,
• with a history of organ or hematopoietic stem cell transplantation or with an indication of hematopoietic stem cell or organ transplantation within 6 months of inclusion,
• with an absolute contraindication to treatment with danazol: active thrombosis or history of thromboembolic disease, porphyria, severe renal or cardiac insufficiency (NYHA stage III or IV), androgen-dependent tumor, uncharacterized mammary nodules, pathological genital hemorrhage of undetermined etiology,
• who have already received danazol for the treatment of telomeropathy,
• having received another androgen within a period of less than 6 months,
• receiving another experimental treatment,
• receiving another hormonal therapy,
• receiving simvastatin,
• having a pregnancy plan and not committing to effective contraception while taking the treatment,
• breastfeeding,
• under guardianship or curators.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Danazol	Danazol 200 MG	Danazol

Primary Outcome Measures

Name	Time	Method
Hematological response or Pulmonary response at M12	12 months	Response at 12 months is defined according to the initial pathology. Responses is defined as a composite outcome. At least one of the following item should be validated to observe response.; * For patients with bone marrow failure, the hematological response at 12 months depending on initial cytopenia(s) is defined by; * 1.5 g/dL increase in hemoglobin without transfusion for 2 months; * And/or increase of 20.10\^9/L in platelet count without transfusion for 2 months; * And/or increase of 0.5.10\^9/L in neutrophils count.; * For patients with pulmonary fibrosis, a decrease of less than 5% in forced vital capacity at 12 months

Secondary Outcome Measures

Name	Time	Method
HDL cholesterol M6	6 months	High-density lipoprotein (LDL) cholesterol blood level in mmol/l
TG M6	6 months	triglycerides blood level in mmol/l
TG M9	9 months	triglycerides blood level in mmol/l
Quality of life evaluation M6	6 months	European Organisation for Research and Treatment of Cancer Quality of Life of Cancer Patients questionnaire (EORTC QLQ-C30, v3.0). The scale range from to 30 to 126 (30 represents the worse quality of life and 126 the best quality of life).; http://www.eortc.be/qol/files/C30/QLQ-C30%20English.pdf
Overall survival	12 months
DLCO M12	12 months	Diffusing capacity of the lung for carbon monoxide (DLCO)
Hepatic tolerance M1	1 month	aspartate aminotransferase blood level
Hepatic tolerance M3	3 months	aspartate aminotransferase blood level
Hepatic tolerance M6	6 months	aspartate aminotransferase blood level
Hepatic tolerance M9	9 months	aspartate aminotransferase blood level
LDL cholesterol M6	6 months	Low-density lipoprotein (LDL) cholesterol blood level in mmol/l
LDL cholesterol M12	12 months	Low-density lipoprotein (LDL) cholesterol blood level in mmol/l
HDL cholesterol M9	9 months	High-density lipoprotein (LDL) cholesterol blood level in mmol/l
TG M3	3 months	triglycerides blood level in mmol/l
Pulmonary parenchymal abnormalities M12	12 months	Evolution of pulmonary parenchymal abnormalities at CT scan
cytological and cytogenetic abnormalities	12 months	Appearance of cytological and cytogenetic abnormalities (bone marrow aspiration with cytogenetic)
Telomere length	12 months	Evolution of the telomere length by Flow Fish
DLCO M3	3 months	Diffusing capacity of the lung for carbon monoxide (DLCO)
PSA M12	12 months	Prostate-specific antigen (PSA) blood level for men
Pulmonary parenchymal abnormalities M6	6 months	Evolution of pulmonary parenchymal abnormalities at CT scan
DLCO M6	6 months	Diffusing capacity of the lung for carbon monoxide (DLCO)
Hepatic tolerance M12	12 months	aspartate aminotransferase blood level
LDL cholesterol M9	9 months	Low-density lipoprotein (LDL) cholesterol blood level in mmol/l
PSA M3	3 months	Prostate-specific antigen (PSA) blood level for men
Hepatic tolerance M2	2 months	aspartate aminotransferase blood level
LDL cholesterol M3	3 months	Low-density lipoprotein (LDL) cholesterol blood level in mmol/l
HDL cholesterol M3	3 months	High-density lipoprotein (LDL) cholesterol blood level in mmol/l
HDL cholesterol M12	12 months	High-density lipoprotein (LDL) cholesterol blood level in mmol/l
TG M12	12 months	triglycerides blood level in mmol/l
PSA M6	6 months	Prostate-specific antigen (PSA) blood level for men
Quality of life evaluation M12	12 months	European Organisation for Research and Treatment of Cancer Quality of Life of Cancer Patients questionnaire (EORTC QLQ-C30, v3.0). The scale range from to 30 to 126 (30 represents the worse quality of life and 126 the best quality of life).; http://www.eortc.be/qol/files/C30/QLQ-C30%20English.pdf
DLCO M9	9 months	Diffusing capacity of the lung for carbon monoxide (DLCO)
Quality of life evaluation M3	3 months	European Organisation for Research and Treatment of Cancer Quality of Life of Cancer Patients questionnaire (EORTC QLQ-C30, v3.0). The scale range from to 30 to 126 (30 represents the worse quality of life and 126 the best quality of life).; http://www.eortc.be/qol/files/C30/QLQ-C30%20English.pdf